Loading stock data…
Beta Bionics, Inc. (BBNX)
$17.00+0.18 (+1.07%)
After Hours$17.00+0.00 (+0.00%)· Last close Jun 29
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Beta Bionics, Inc. in the Healthcare sector is trading at $17.00 with a market capitalization of $555M. Wall Street consensus targets $19.18 (11 analysts), implying a +12.8% move over the next 12 months. The stock is currently 48% below its 52-week high of $32.71, remaining 6.9% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +12.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $27.63M↓ | $32.12M↑ | $27.25M↑ | $23.24M↑ | $17.64M |
| Gross Profit | $16.44M↓ | $18.94M↑ | $15.12M↑ | $12.50M↑ | $8.97M |
| Operating Income | -$24.27M↓ | -$16.12M↑ | -$17.04M↑ | -$19.87M↓ | -$18.64M |
| Net Income | -$21.89M↓ | -$13.47M↑ | -$14.21M↑ | -$16.87M↑ | -$28.66M |
Peer Comparison
JNJUNHPFE
Fundamentals
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas,...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$554.79M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-24.49%
Volume
Today's trading volume
695,663
Recent News
Beta Bionics to launch its first insulin patch pump to compete with Insulet
The device called Mint, which would work with the company’s adaptive insulin dosing algorithm, is expected to debut in the first half of 2027.
Kestra Medical Grew Revenue 63%. One Fund Still Trimmed 351,000 Shares
Kestra Medical Technologies develops advanced wearable cardiac devices and digital health solutions for cardiovascular care providers.
Robert Bruce's Strategic Moves: A Closer Look at Beta Bionics Inc's Impactful Addition
Exploring the Latest 13F Filing and Investment Strategies
Beta Bionics Touts Pharmacy Push, iLet Momentum and 2027 Mint Patch Pump Plans
Beta Bionics (NASDAQ:BBNX) Chief Financial Officer Stephen Feider said the company’s first-quarter outperformance was supported by increasing use of the pharmacy reimbursement channel, expanded sales coverage and growing confidence in the company’s iLet insulin pump platform. Speaking at a Bank of
Here's Why We're Not Too Worried About Beta Bionics' (NASDAQ:BBNX) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...